ASMPT (00522.HK) -5.650 (-6.420%) Short selling $218.03M; Ratio 18.607% reported weaker-than-expected 2Q24 results, and guided a 6.4% QoQ decline in 3Q24 revenue, missing the expectations of Morgan Stanley/ the market by 17%/ 20% respectively, Morgan Stanley issued a research report saying.
Morgan Stanley had previously expected a modest recovery in the mainstream market, but now it looks like the weakness could last longer than expected, especially in markets outside China.
Related NewsASMPT Interim NP $315M, Down 49.6%; Interim Div. $35 Cents
Morgan Stanley kept rating at Overweight on ASMPT, with a target price of $130, saying that the stock's sell-off is an attractive market entry opportunity. The broker expected a seasonal recovery in 4Q24.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-24 16:25.)
AAStocks Financial News
Check whenever you want
WikiStock APP